Brief: Milestone Pharmaceuticals Announces FDA Acceptance Of New Drug Application For Cardamyst™
29/05/2024 12:06
May 29 (Reuters) - Milestone Pharmaceuticals Inc
MIST.O :
* MILESTONE PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW
DRUG
APPLICATION FOR CARDAMYST™
* MILESTONE PHARMACEUTICALS INC: FDA PRESCRIPTION DRUG USER
FEE
ACT (PDUFA) TARGET DATE IS 10 MONTHS FROM ACCEPTANCE DATE OF MAY
26, 2024.
Source text for Eikon: ID:nGNX7bl1mG
Further company coverage: MIST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview